echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Treatment of bald Lilly JAK inhibitors was recognized by the FDA for breakthrough therapy.

    Treatment of bald Lilly JAK inhibitors was recognized by the FDA for breakthrough therapy.

    • Last Update: 2020-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Baldness is a sudden limitation of plaque-like hair loss, no difference in the incidence of men and women, can occur at any age, but with youth and adults more common.
    the cause of baldness is unknown, but there are lymphocytes soaked around the follicles, and sometimes combined with other autoimmune diseases (such as vitiligo, ad hoc dermatitis), so it is also believed that the occurrence of spot baldness may have an autoimmune pathogenesis.
    hairs in the bald areas are multi-renewable, but they can also be recurrent.
    FDA has not approved any drugs to treat baldness.
    FDA's decision is based primarily on the positive results of the II/III BRAVE-AA1 study.
    in Phase II, 36 weeks of treatment results showed that no new serious adverse events were detected compared to placebo, and the treatment-related adverse events were mild to moderate, including upper respiratory tract infections, nanussitis, and acne.
    based on the interim analysis of the brave-AA1 study phase II, the BRAVE-AA1 study Phase III and another Phase III study, codenamed BRAVE-AA2, have been initiated to assess the efficacy and safety differences between baricitinib 2mg and 4mg placebos.
    baricitinib is a JAK1/2 inhibitor currently approved for the treatment of moderate to severe rheumatoid arthritis in adults.
    JAK kinase is an intracellular family of non-receptor tyrosine kinase with four members, JAK-1, JAK-2, JAK-3 and TYK-2.
    the signaling conduction of most cytokines in JAK kinase-mediated cells, such as interleukin (IL), interferon (IFN), etc., and different receptors activate different subtypes of JAK kinases to perform differentiated biological functions.
    therefore, the potential indications of JAK inhibitors are also very diverse.
    the development of baricitinib's indications also include systemic lupus erythematosus, adhesterisive dermatitis, psoriasis and so on.
    Source: Lotus Mallbris, Vice President of Immune Product Development at Next Pharma Lilly, Pharmaceutical Rubik's Cube, said: "No FDA-approved drugs are currently available in patients with baldness.
    baldness not only causes local hair loss in the patient's body, but also causes a huge mental burden on the patient.
    Lilly expects to be able to offer the first therapeutic drug option for patients with baldness.
    "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.